ABSTRACT: In this study, we describe novel inhibitors against Francisella tularensis SchuS4 FabI identified from structure-based in silico screening with integrated molecular dynamics simulations to account for induced fit of a flexible loop crucial for inhibitor binding. Two 3-substituted indoles, 54 and 57, preferentially bound the NAD + form of the enzyme and inhibited growth of F. tularensis SchuS4 at concentrations near that of their measured K i . While 57 was species-specific, 54 showed a broader spectrum of growth inhibition against F. tularensis, Bacillus anthracis, and Staphylococcus aureus. Binding interaction analysis in conjunction with site-directed mutagenesis revealed key residues and elements that contribute to inhibitor binding and species specificity. Mutation of Arg-96, a poorly conserved residue opposite the loop, was unexpectedly found to enhance inhibitor binding in the R96G and R96M variants. This residue may affect the stability and closure of the flexible loop to enhance inhibitor (or substrate) binding.
■ INTRODUCTION
Francisella tularensis is a facultative intracellular Gram-negative bacterium responsible for the disease tularemia. F. tularensis is classified as a tier 1 Select Agent as it could potentially be used as a biological weapon. It can incapacitate or cause death with doses as small as 25 colony-forming units. 1 Without treatment, the mortality rate can be as high as 5−15% for type A strains and 30−60% for the severe systemic and pneumonic forms of the disease. 2 Of the antibiotics that have been proven to be effective, streptomycin was historically the preferred treatment for tularemia. 1, 3 However, it and other aminoglycosides such as gentamicin have been associated with ototoxicity (irreversible cochlear and vestibular damage) 4 and nephrotoxicity 5 and require parenteral administration. 3, 6, 7 While ciprofloxacin is an easily administered oral antibiotic effective against experimental infections with F. tularensis SchuS4, 8 resistance to ciprofloxacin can arise from single-point mutations within a region of DNA gyrase known as the quinolone resistance-determining region (QRDR). 9, 10 Ciprofloxacin-resistant strains of F. tularensis,
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Bacillus anthracis, 12 Yersinia pestis, 13 Escherichia coli, 9, 14 and Streptococcus pneumoniae 15, 16 are well documented, 11 and ciprofloxacin resistance in E. coli and Pseudomonas aeruginosa is now ≥40%. 17, 18 Thus, there continues to be a need to identify new drugs effective against tularemia that are safe and practical to administer.
The viability of F. tularensis, as well as that of a variety of other Gram-negative and Gram-positive bacteria such as E. coli, Staphylococcus aureus, and Bacillus subtilis, is highly dependent upon its type II fatty acid synthesis pathway (FAS II). The FAS II pathway differs distinctly from the mammalian type I multienzyme fatty acid synthase (FAS I) making the monofunctional enzyme components of the FAS II pathway ideal targets for selective inhibition. FabI, a NADH-dependent enoyl acyl carrier protein reductase (ENR) (EC 1.3.1.9), serves to catalyze the final reaction in the chain elongation cycle (eq 1). 19, 20 However, at least three other ENR isozymes, FabK, FabL, and FabV, can catalyze the same reaction as FabI in fatty acid biosynthesis. 21−23 FabK 22 is structurally unrelated to FabI, FabL, and FabV and is resistant to triclosan; 24 its presence can thereby confer triclosan resistance. FabL and FabV are structurally similar to FabI, but share low sequence identity and are poorly inhibited by triclosan. 25, 26 S. pneumoniae and P. aeruginosa contain FabK, 24 and Vibrio cholerae, 27 P. aeruginosa, 28 Y. pestis, 29 and Burkholderia mallei 30 contain FabV. FabI is the sole ENR in F. tularensis, B. anthracis, E. coli, and S. aureus. Because F. tularensis and S. aureus FabI are essential for lipid biosynthesis even in the presence of exogenous lipids, 31−33 FabI is an attractive target for antimicrobial drug design. 34 Triclosan, diazaborines, and the frontline antituberculosis drug, isoniazid, have all been shown to inhibit ENRs. Triclosan, the most well-known of these inhibitors, is a biphenyl ether that has been used ubiquitously as an antimicrobial additive in hand soap, toothpastes, mouth rinses, and other such consumer products (in the range of 0.1−0.3% of product weight) for over 25 years. 35−37 However, a variety of adducts (glucose, mercapturic acid, and cysteine conjugates) form with the biphenyl rings in vivo and the compound is rapidly cleared from the blood and excreted in the urine, making it ineffective as an oral antibiotic. 38 While several species-specific FabI inhibitors have been identified, 39 broad spectrum inhibition of FabI enzymes has been particularly difficult. Structurally, FabI contains a characteristic and mostly conserved substrate binding site which is shielded by a highly flexible loop (residues 192−205 in F. tularensis FabI). 26, 40 Triclosan preferentially binds the NAD + product complex, and the loop is found clamped down in a closed form. 41 Because triclosan inhibition of FabI exhibits slow-onset kinetics, indicative of the ordering of the substrate binding loop, it is believed that the loop stabilization upon inhibitor binding is a key determinant of binding affinity and selectivity. 19,41−43 Structure-based virtual screening has been successfully applied to the identification of small molecule inhibitors against specific targets. For pathogens which require BSL3/4 environments, high throughput screening of chemical libraries using cell-based assays is not typically practical, thus computational methods in combination with in vitro assays offer an appealing alternative to antimicrobial drug discovery. The X-ray crystal structures of FabI, free and bound to triclosan, have recently been determined. 19, 44, 45 Insights into the binding interaction of triclosan in the active site and dynamic properties associated with the flexible substrate binding loop allowed us to carry out structure-based in silico screening to search large-scale databases for novel inhibitors against FabI. The combination of molecular dynamics with docking protocols has been proposed to be more effective than molecular docking alone, 46 but must be optimized for screening particular target proteins. Herein we describe the use of a combination of in silico high throughput screening, modeling, and kinetic analyses to identify inhibitors of F. tularensis FabI with novel chemotypes.
■ METHODS
Reagents. All buffers, substrates, and solvents were purchased from Sigma (St. Louis, MO). Ciprofloxacin was purchased from the U.S. Pharmacopeia as a certified reference standard, 100.0% pure (Rockville, MD). All compounds were purchased from ChemNavigator. Purity was determined by LC-ESI-MS by analyzing the HPLC chromatograms, masses, and isotopic distributions. Inhibitors 41, 54, and 57 were 86, 84.5, and >99% pure, respectively, and were from the Aldrich Market Select screening compound collection ( 1 H NMR and mass spectra are provided in the Supporting Information).
Protein Purification and Expression. The pet23b expression plasmid carrying FtuFabI with a C-terminal His 6 -tag was synthesized by Genscript, Inc. (Piscataway, NJ). The plasmid was transformed into BL-21 (DE3) pLysS E. coli (Novagen). The cells were grown at 37°C until reaching an OD 600 of 0.8−1.0 before induction with 0.2 mM IPTG. The cells were harvested after an overnight induction period at 17°C. The cells were lysed and sonicated and loaded onto a nickelcharged Chelating Sepharose column (GE Healthcare) equilibrated with buffer containing 20 mM Tris pH 7.6 and 500 mM NaCl. For the mutants, 5% glycerol was added to the buffers. The column was washed with buffer containing 60 mM imidazole, and the protein was eluted with buffer containing 300 mM imidazole. The protein was further purified using a Superdex G-75 column (GE Healthcare) equilibrated with 30 mM PIPES pH 8.0, 150 mM NaCl, and 1 mM EDTA. Protein concentration was determined using a calculated extinction coefficient of ε 280 = 17.670 mM −1 cm −1 and a molecular weight of 28,870 Da.
In Vitro Assays. Two methods of detection, fluorescence and UV−vis, were used to monitor the oxidation of NADH to NAD + . 19 3°C) . Data was globally fit to a velocity equation for a bisubstrate system with ternary complex formation (random order) using Grafit 6.0 (Erithacus Software Limited). K A ′ is the dissociation constant for the binary EA complex, and K A and K B are the Michaelis constants for substrates A and B, respectively (Scheme 1).
Effect of NAD + on K i ′. To determine if the inhibitors selectively bound the NAD + complex apparent inhibition constants, K i ′, were measured using a saturating concentration (200−333 μM) of NAD + . FtuFabI (160 nM) was added to NAD + , NADH (12.5−500 μM), and inhibitor (2.5−12 μM). The reactions were initiated with CrCoA (160 μM) and monitored at 340 nm for 5 min.
Testing of FabI Inhibitors on Growth of Francisella tularensis and Bacillus anthracis. Minimum inhibitory concentrations (MICs) were determined by the microdilution method in 96-well plates according to Clinical Laboratory Standards Institute guidelines. 48 Escherichia coli (ATCC25922), Pseudomonas aeruginosa (ATCC 27853), or Staphylococcus aureus (ATCC 29213) were used for internal quality control. F. tularensis (SchuS4) and B. anthracis (Ames) were from the U.S. Army Medical Research Institute of Infectious Diseases collection.
FabI inhibitors were dissolved in DMSO (Sigma-Aldrich, St. Louis, MO). Ciprofloxacin was used as a comparator antibiotic. The inhibitors and comparator were thawed and immediately diluted 1:20 into freshly prepared Cation-Adjusted Mueller−Hinton Broth (CAMHB) (Becton Dickinson, Franklin Lakes, NJ) to generate working stocks. Then 50 μL of the FabI inhibitor or comparator antibiotic working stock solutions were placed into wells of the first column of a 96-well plate and serially diluted in CAMHB. To these wells, 50 μL of freshly prepared bacterial inocula were added. DMSO without inhibitor was used for comparison and showed no inhibitory activity against any of the bacteria tested.
Bacterial inocula were prepared by serial passage (twice) and incubation at 35 ± 2°C on agar plates using starting samples removed from freezer stocks of each strain. Chocolate agar was used for F. tularensis and sheep blood agar for B. anthracis, E. coli, P. aeruginosa, and S. aureus. Colonies were taken from the second passage plate and suspended, with gentle vortexing, into CAMHB for B. anthracis, E. coli, P. aeruginosa, and S. aureus, or CAMHB+4%IsoVitalX (Becton Dickinson) for F. tularensis. Suspended cultures were diluted with CAMHB (+4%IsoVitalX for F. tularensis) to the desired bacterial cell density based on OD 600 . Following the addition of 50 μL of the diluted bacterial inocula to each well containing serially diluted FabI inhibitor (at 50 μL volume), the resulting final bacterial concentration was approximately 5 × 10 4 CFU/mL. Plates were incubated in air at 35 ± 2°C. MICs (first well with no visible growth) were determined visually at 18−24 h for B. anthracis, E. coli, P. aeruginosa, and S. aureus or 42−48 h for F. tularensis. The antibiotic or inhibitor ranges covered were 8−0.004 μg/mL (ciprofloxacin), 52−0.26 μg/mL (compound 41), 343−0.17 μg/mL (compound 54), and 413−0.202 μg/mL (compound 57).
Cytotoxicity Assays. 786-O (ATCC CRL-1932), a human renal cell adenocarcinoma line, and Neuro-2a (ATCC CCL-131), a mouse neuronal line, were maintained in Eagle's Minimum Essential Medium and RPMI-1640 medium, respectively, both supplemented with 10% fetal bovine serum and penicillin/streptomycin (50 units/mL, 50 μg/ mL). The day before compound addition, 10 3 cells/well were plated in 96-well plates in their respective media and incubated overnight at 37°C under 5% CO 2 . The next day, the test compounds were added after making 2-fold serial dilutions in DMSO. The concentrations of the compounds were dependent on their solubility in DMSO, and an equivalent amount of DMSO was added to control wells. Following compound addition in triplicate, cells were incubated at 37°C under 5% CO 2 for 72 h. The cells were then washed with PBS and CellTiter 96 Aqueous One solution was added to each well and the plates were incubated for 2 h at 37°C. The absorbance at 490 nm was read, and percent survival (relative to the DMSO control) was used to determine the 50% lethal concentration (LC 50 ) using GraFit 6.0.1 software (Erithracus Software Limited).
Modeling of FabI−NAD−Triclosan Binding Complex. The three-dimensional structure of FabI from F. tularensis was obtained from the Protein Data Bank (PDB code 2JJY). 49 The structure is a tetramer in complex with the cofactor, NAD, bound in the active site. However, the substrate-binding loop (192−205) is disordered in the crystal structure. Experimental studies have shown that triclosan (TCL) is a slow-onset inhibitor that induces conformational changes in the loop and stabilizes the inhibitor in a closed form in the inhibitorbound complex. 45 Therefore, we modeled the substrate binding loop of FtuFabI in the presence of the NAD cofactor and triclosan and generated the A monomer (Supporting Information Figure S1 ). The NAD complex was extracted, and all water molecules were removed. The substrate-binding loop was constructed using the program Modeler 50 with a homologue template of FabI from E. coli in complex with triclosan (PDB 1QSG, 45 identity 57%). The binding complex of FtuFabI−NAD−TCL was energy-minimized using the AMBER 11 package. The refined structural model of FtuFabI in the presence of NAD was used for the following in silico screening.
Virtual Screening: Round I. The AutoDock-based DOVIS program 51, 52 was used to screen the NIH Molecular Library Small Molecule Repository (MLSMR) collection of ∼350000 compounds against the structure model of FtuFabI−NAD. The active site of the protein was defined by a grid of 60 × 60 × 60 points with a grid spacing of 0.35 Å centered at the center of mass of NAD. The Lamarckian Genetic Algorithm (LGA) was used with 50 runs, and clustering of docked poses was applied according to the RMSD. The best pose with lowest AutoDock score of the top three clusters were retained for each compound. The predicted binding poses of the entire database were ranked by AutoDock score overall, and the top 20000 compounds were extracted. Two steps of postprocessing were utilized for hit selection. First, the retrieved 20000 compounds were energyminimized in the binding site of FabI followed by rescoring with three different scoring functions (AutoDock 4.0, LigScore 2, and X-SCORE). The top 500 compounds from each score list were pooled, and duplicates were removed. Second, the resulting unique compounds (∼1000 compounds) were subjected to a short MD simulation (100 ps) in implicit solvent, and the binding free energies were calculated with the MM-PBSA method. Finally, the top-ranked 200 hits were visually inspected and 75 commercially available compounds were cherry picked for experimental evaluation.
Virtual Screening: Round II. A recent X-ray crystal structure of FabI from F. tularensis (FtuFabI) bound to NAD + and triclosan (PDB code 3NRC) 44 was reported after the start of round I virtual screening. The complete structure of FtuFabI including the structured substrate binding loop was determined in this crystal structure. In an effort to identify FabI inhibitors with new scaffolds, we carried out a second round of virtual screening using PDB 3NRC. The ChemNavigator database contains ∼14 million unique compounds and was screened using the 2D similarity search option in Pipeline Pilot. Six known FabI inhibitors that were cocrystallized with other FabI were collected and used as query molecules. The molecules were obtained from PDBs 2OP0 (P. falciparum), 53 3OIG (B. subtilis),
56 1LXC (E. coli), 56 and 1MFP (E. coli) 57 (Supporting Information Figure S2 ). The top 2000 most similar molecules were selected and subjected to hierarchical virtual screening protocol in the Glide program. 34−36 In addition, 1150 approved drugs from the DrugBank 58 were screened using a similar protocol, combined Glide XP docking and a 3D-ligand based similarity search program, ROCS. 59 Finally, the top-ranked 200 hits were visually inspected and 65 commercially available compounds were selected for experimental evaluation.
MD Simulations and Binding Free Energy Calculations. MD simulations were conducted for the optimized binding mode of inhibitors with FabI in explicit solvent using the AMBER 11 package and the ff99SB force field. 60 The solvated protein systems were subjected to a thorough energy minimization prior to MD simulations by first minimizing the water molecules while holding the solute frozen (1000 steps using the steepest descent algorithm), followed by 5000 steps of conjugate gradient minimization of the whole system to remove close contacts and to relax the system. A nonbonded cutoff of 10 Å was used, and the nonbonded pair list was updated every 25 time steps. Periodic boundary conditions were applied to simulate a continuous system. The particle mesh Ewald (PME) method was employed to calculate the long-range electrostatic interactions. 61 The simulated system was first subjected to a gradual temperature increase from 0 to 300 K over 100 ps and then equilibrated for 500 ps at 300 K, followed by production runs. Constant temperature and pressure (300 K/1 atm) were maintained using the Berendsen coupling algorithm 62 with a time constant for heat-bath coupling of 0.2 ps.
The binding free energies were calculated using the MM-PBSA method. 63 A set of 100 snapshots was extracted from trajectories of binding complexes at 10 ps intervals from the 2 ns of each MD simulation. The polar contribution (G PB ) was calculated using the Poisson−Boltzmann equation. The nonpolar contributions (G SA ) were estimated using the MSMS algorithm according to the equation: G SA = γ × SASA + b kcal/mol, with γ and b set to 0.00542 kcal/mol·Å −2 and 0.92 kcal/mol, respectively, and the probe radius used to calculate the solvent accessible surface area (SASA) was set to 1.4 Å. The entropy contribution was neglected in the binding free energy calculation. Binding free energy decomposition was performed using the same MM-PBSA module in AMBER 11 package. Figure S1 ). As shown in the FtuFabI−NAD + −triclosan complex (PDB 3NRC) 44 ( Figure  1 ), the planar aromatic ring of triclosan carrying the hydroxyl group binds in the interior of the pocket (A-ring binding site) and makes a π−π interaction with the nicotinamide group of the NAD cofactor. While the 5-chlorophenyl group points toward Pro-191 and forms stacking interactions with Tyr-146 and Phe-203, the hydroxyl group forms a hydrogen-bond with the side chain of residue Tyr-156, which is essential for the activity of triclosan. 36,41,44,68−70 Residues from the flexible loop including Ala-197, Ile-200, and Phe-203 form the wall of the hydrophobic pocket, and structure-based sequence alignment showed that these residues are mostly conserved (Supporting Information Figure S1 ). On the other hand, the dichlorophenyl ring of triclosan is orientated toward the hydrophobic entrance of the pocket (B-ring binding site). This region mainly consists of residues Phe-93, Leu-99, Lys-163, Tyr-156, and Met-159, which are also typically conserved among species. Arg-96 is located at the top of the entrance of the B-ring binding site opposite of the substrate binding loop but is poorly conserved. In addition, the oxidized cofactor NAD + makes significant contributions to the inhibitory activity of triclosan by forming extensive interactions with both the A and the B rings of triclosan.
Structural Model of FtuFabI. The substrate binding loop of FabI, which is disordered in the structure 2JJY, 19 was modeled with the cofactor and triclosan using EcFabI as a template (1QSG 45 ) (Supporting Information Figure S1 ). The FtuFabI−NAD + −triclosan complex was further refined with MD simulations. Compared to the later released crystal structure 3NRC, 44 which has complete coordinates for the loop residues and was used in the second round of screening, the refined structural model of FtuFabI showed the same 3D Figure S1 ). While small differences were observed, triclosan interacted with the substrate binding loop in a similar manner in both the modeled structure and crystal structure. A notable difference was found in the side chain of Arg-96, which pointed downward, whereas the side chain was oriented away from the loop in the triclosanbound crystal structure (3NRC). 44 In 3NRC, R96 had higher B-factor values suggesting static or dynamic disorder of the side chain. The role of Arg-96 in inhibitor and substrate binding is discussed below.
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Virtual Screening Hits. We performed two rounds of virtual screening using structural and ligand-based approaches to search the MLSMR and ChemNavigator databases ( Figure  2 ). Structure-based docking was performed in the first round screen for the MLSMR library (∼340000 unique compounds) using the structural model of FabI, followed by MD simulations and MM-PBSA calculation of top hits in the postprocessing for hit selection. The second screen was performed using a fast 2D-similarity searching method for the large ChemNavigator database (over 14 million compounds). The top hits were prioritized with a hierarchical docking approach. For drugrepurposing, a small library of FDA approved drugs was also screened. The results of identified hits were summarized in Figure 3 and Supporting Information Figure S2 .
The three most potent hits with low micromolar inhibitory activity, inhibitors 41, 54, and 57, were identified from the firstround of screening. The measured K i values were K i (41) = 7 ± 2 μM, K i (54) = 3.4 ± 0.7, and K i (57) = 12 ± 3 μM. Compound 41 is a phenyl oxadiazole derivative with a sulfonylpyrrolidine group, whereas 57 and 54 contain a 3-substituted indole group. An N-methyl indole inhibitor identified at GSK was shown to have inhibitory activity against S. aureus, H. influenzae, and S. pneumoniae 71 (Supporting Information Figure  S3 ). The F. tularensis FabI inhibitors identified by Hevener et al. contain a structurally similar benzoimidazole group (Supporting Information Figure S3) . 52 In comparison, our 3-substituted indole inhibitors appear to possess a distinct scaffold that differs from these known FabI inhibitors. Surprisingly, no interesting hits were identified from the second round of screening using a similarity search. These hits were generally weak binding inhibitors (IC 50 47−79 μM) and not suitable for antimicrobial activity. We believe that the robust performance of the firstround of screening was gained from the MD simulations in combination with MM-PBSA scoring. This approach has been applied to drug discovery with various targets to account for protein flexibility and inhibitor-induced fit. 46 These effects are especially relevant to the binding of FabI inhibitors because the flexible substrate-binding loop is known to undergo conformational changes which stabilize inhibitor binding in the closed form (Figure 1, Supporting Information Figure S1 ). 41, 42, 45 Binding Mode Analysis. The binding interactions of the three identified inhibitors to FabI (41, 54, and 57) were further investigated with MD stimulations and binding free energy calculations. Similar to triclosan and other known inhibitors observed in cocrystal structures, these small molecule inhibitors were well accommodated in the active site of FabI. The inhibitors made interactions with mostly conserved residues in the A-and B-ring binding pockets (Figure 4 ). An interesting finding is that the two indole-based inhibitors adopted different binding conformations. The indole group of 57 was found to occupy the interior of the A-ring binding pocket, forming a stacking interaction with Tyr-146, Phe-203, and the nicotinamide group of NAD, whereas 54 adopted a binding conformation with the indole pointed outward to the B-ring binding site and made extensive interactions with Phe-93 as well as residues in the flexible loop 192−205. MD stimulations indicated that the binding complex remained stable while the loop was significantly stabilized. The calculated binding free energies of the three inhibitors were in agreement with experiments of measured K i (Supporting Information Figure S4 and S5).
Further binding free energy decomposition revealed more details of key residues that contributed to the binding interactions ( Figure 4 ). Tyr-146 had the largest contributions to the binding free energies of all three inhibitors, reiterating the importance of this H-bonding interaction commonly found with known FabI inhibitors. Tyr-156 and Met-159 in the interior of the binding pocket also played an important role in inhibitor binding by forming extensive π-stacking and hydrophobic interactions. Remarkably, residue Phe-93 had the largest binding energy contributions to inhibitors 41 and 57 at the Bring binding site, while the loop residues such as Ala-197 and Phe-203 contributed greatly to inhibitor 54 binding. These predictions were utilized to select several of the site-directed mutants for kinetic analysis.
Inhibitors Preferentially Bind the E−NAD + Complex. Triclosan specifically binds the NAD + bound form of the enzyme in a slow-onset manner with the ordering of the substrate binding loop. 44 In E. coli FabI, the substrate binding loop has also been shown to become structured upon binding acyl carrier protein but in a slightly different conformation than that observed in the NAD + −triclosan complex. 41 Because the in silico screening began with a modeled loop between residues 192−205 the impact of this model on the inhibitor binding specificity was not known for the compounds selected from the in silico screening, thus kinetic methods were employed to examine inhibition of the NADH-bound form and the NAD + -bound form. The three inhibitors were found to be in rapid equilibrium and no evidence of slow-onset inhibition was apparent in progress curves (Supporting Information Figure S6 Figure 5 and Supporting Information Figure S7 ). The inhibitors affected the slope (K m /V max ) but not the intercept (1/V max ), consistent with competitive inhibition with respect to the CrCoA substrate ( Table 2 ). The preferential binding of the inhibitors to the NAD + form versus the NADHbound form also demonstrated specific binding and showed that the observed inhibition was not due to nonspecific effects such as denaturation, aggregation, unwanted side-reactions with substrates, or interference in the detection of product formation because the same inhibitor concentrations were tested in the presence and absence of NAD + . This result was also consistent with the predicted contribution of the cofactor to the binding free energy (Figure 4 ). Site-Directed Mutagenesis and Kinetic Analysis. On the basis of the predicted binding interactions and binding free energy analysis, seven variants (F93V, R96M, R96G, Y156F, M159T, A197M, and F203L) were constructed to examine the effects of these mutations on inhibitor binding using sitedirected mutagenesis and kinetic analysis. To obtain the steady state kinetic parameters, initial velocities were measured and both CrCoA and NADH concentrations were varied in threedimensional kinetic experiments (Supporting Information Figure S8 ). The data was globally fit to eq 2. In Lineweaver− Burk plots of 1/v vs 1/[CrCoA] and 1/v vs 1/[NADH], the lines converged indicating a sequential (ternary complex) mechanism rather than a substitution mechanism (ping-pong). In both plots, the lines converged on the abscissa, indicating that the binding of the first substrate had a small effect on the binding of the second (i.e., random-order ternary complex mechanism) (Supporting Information Figure S8 ). The formation of a ternary complex suggests direct transfer of the hydride to the substrate rather than to the enzyme (Supporting Information Figure S9 ). ENR with both types of kinetic mechanisms have been described in the literature.
72−74 The Table 1 . Three of the selected variants (Y156F, M159T, and F203L) have been associated with triclosan resistance. 36, 37, 75, 76 Of the seven variants, only four had measurable activity, F93V, R96M, R96G, and F203L (Table 1) . The F93V and F203L variants had significant reductions in activity (126−190-fold reduction in k cat ). The k cat of the F93V variant was 190-fold lower than WT, however, no significant effect on the Michaelis constants for NADH and CrCoA was observed (<2-fold different), suggesting that F93 plays an important role in product release and/or catalysis. The F203L variant showed a similar decrease in activity (127-fold decrease) and no significant effect on the K m (NADH) but a large 8-fold increase in the K m (CrCoA), suggesting a role in substrate binding, catalysis, and/or product release. The locations of F93 and F203 are shown in Figure 1 .
Phe-93 lies in the entrance of the substrate binding pocket, whereas the side-chain of Phe-203 is directed toward the interior of the pocket and is one of the substrate binding loop residues (residues 192−205).
The R96G and R96M mutations had an unusual effect. Arg-96 is present in FtuFabI but is substituted by glycine in E. coli and P. aeruginosa and a methionine in S. aureus. Arg-96 is opposite of the flexible substrate-binding loop (Supporting Information Figure S1 ) and can be found in two different conformations in the triclosan-bound and free structures. 19, 44 In the WT, K m approximately equals K s , while in the mutants, K m < K s (Table 1) . A thermodynamic box relating the constants with a proportionality constant called α is shown in Scheme 1. 77 When α = 1, the two sites are considered noninteracting; when α < 1 or α > 1, this indicates that the two sites interact (either tightening or weakening the binding of the second (Table 1) . Similar effects (i.e., tighter binding of inhibitors) were observed on the IC 50 values. Therefore, interaction between the two sites may enable higher affinity substrate (or inhibitor) binding by stabilizing the flexible loop closure through either a new interaction or enhancement of an existing interaction.
Effects of Mutations on Inhibition. To determine if one or more of the identified chemotypes were affected by mutation, we measured the IC 50 values of inhibitor 41, 54, 57, and triclosan (Table 3) . Of the three inhibitors, 57 showed the smallest increase (3-fold) in its IC 50 value with the F93V variant. Both 41 and 54 showed significant increases (>14-fold and >6-fold increases, respectively) in the IC 50 values when measured with the F93V variant, and the IC 50 values were >125 μM. Binding mode analysis showed that Phe-93 formed extensive vdW and aromatic stacking interactions and made significant binding free energy contributions to all three inhibitors ( Figure 4) . Notably, Phe-93 was predicted to make greater contributions to the binding free energies of 41 and 54 and a smaller contribution to 57. Inhibitor 41 was not affected by the F203L variant, suggesting that this residue does not strongly contribute to its binding. In contrast, the IC 50 values of 54 and 57 were found to increase by 4-and 5-fold, respectively. These results are consistent with the predicted binding mode and binding free energy analysis (Figure 4) .
The effects of the Arg-96 mutations on inhibition were unexpected. The IC 50 values for triclosan with the R96M and R96G variants were 4−26-fold lower. For inhibitor 41, 10-and 45-fold decreases were observed for R96G and R96M, respectively. Similarly, 5-and 10-fold decreases were observed for inhibitor 57 with the R96M and R96G variants, respectively. The IC 50 values for inhibitor 54 with the R96M and R96G variants were 1.7 and 6-fold lower, respectively. These results were rather surprising because the binding free energy analysis predicted that Arg-96 made only minor contributions. This suggested that the mutations enhanced or created new interactions with the inhibitor in some other manner. The importance of loop closure to substrate binding was previously demonstrated by mutation of the loop residue, Lys-201 to Glu, in E. coli FabI, which abolished activity. 41 Arg-96 is located opposite to the substrate binding loop at the exterior of the binding site and could alter the loop flexibility and closure, consequently affecting inhibitor binding (Supporting Information Figure S1 ). To investigate this hypothesis, we examined the loop dynamics of the R96M and R96G variants in comparison with the wild-type using MD simulations and binding free energy calculations (Supporting Information Figure S10 ). The loop of the wild-type FabI in the apo state remained stable in a closed form during the time course of MD simulations, whereas it became more dynamic in the R96G and R96M variants. The more flexible loop may better accommodate the inhibitor (or substrate). 42 Additionally, binding mode analysis showed that the indole group of inhibitor 54 could now interact with the substrate binding loop residue, Gly-199, through a new hydrogen bonding interaction, potentially altering the loop mobility in the inhibitor-bound state ( Figure 6) .
Cytotoxicity of Inhibitors. The cytotoxicity of inhibitors was determined using a colorimetric cell proliferation assay to measure cell survival in two cell lines, 786-O (human kidney) and Neuro2a (mouse neuronal) ( Table 4) . Inhibitor 41 had comparable toxicity when compared to triclosan. Inhibitors 54 and 57 were less toxic than triclosan for both cell lines. Further refinement of the chemotypes is needed to improve the therapeutic indices of these compounds.
Effect of Inhibitors on Bacterial Growth. Inhibitors 41, 54, and 57 were tested against F. tularensis, B. anthracis, E. coli, P. aeruginosa, and S. aureus (Table 5 ). Inhibitor-41 was not effective at inhibiting bacterial growth. Inhibitor 57 was shown to inhibit the growth of F. tularensis SchuS4 in a species-specific manner. The measured MIC = 12.9 μg/mL (39 μM) was comparable to the kinetically measured K i of 12 ± 3 μM. It is important to note that the MIC is the concentration at which all bacterial growth is halted, while the IC 50 is the concentration at which 50% inhibition is observed. Here we found that the MIC and K i were closely correlated for inhibitor 57, consistent with target-specific inhibition and minimal removal by bacterial efflux pumps. (Table 3) ) of inhibitor 54 and 57 differed by 7-fold. Its MIC for F. tularensis (MIC = 22 μg/mL (67 μM)) was comparable to that of inhibitor 57. We believe the discrepancy arose from the low solubility of compound 54 and that the K i = 3.4 ± 0.7 μM is more representative of the inhibitory activity of inhibitor 54 as the K i was measured using lower concentrations of the inhibitor where precipitation was not observed; the compound was soluble in our in vitro assay buffer at 125 μM (Table 6 ). Inhibitors 54 and 57 were comparably effective in antimicrobial activity when compared to a tighter binding inhibitor (IC 50 = 0.3 μM) previously identified and optimized by Hevener, et al., 78 which had a MIC of 7.8 μg/mL (26 μM).
Of the top three hits, inhibitor 54 showed a broader spectrum of growth inhibition against F. tularensis, B. anthracis, and S. aureus (Table 5 ). In contrast, 57 was species-specific. Binding mode analysis indicated that inhibitor 54 bound at the active site of FtuFabI differently from inhibitor 57. The indole group of 54 pointed outward and interacted closely with the substrate binding loop and was adjacent to residue Arg-96. Arg-96 varied across species but was conserved in B. anthracis FabI; Arg-96 was replaced by a Met in S. aureus and a Gly in E. coli and P. aeruginosa. Because decreases in the IC 50 values were observed for the R96G and R96M variants, we hypothesized that growth inhibition would be observed in these other bacterial species. As predicted, inhibitor 54 did inhibit bacterial growth in F. tularensis, B. anthracis, and S. aureus, but unexpectedly had no effect on the growth of E. coli. Conversely, inhibitor 57, which had a lower IC 50 in the R96G and R96M variants, had no effect on the growth of B. anthracis, E. coli, or S. aureus. Notably, these substitutions had smaller effects on the binding of inhibitor 54 when compared to the other inhibitors including triclosan. This suggests that the binding mode of the 3-substituted indole, which is predicted to differ for 54 and 57, may be important for achieving broader spectrum inhibition; however, other mechanisms cannot be excluded.
Our MD simulations showed that the substrate binding loop was significantly stabilized upon inhibitor binding (Supporting Information Figure S5 ). The loop stabilization can also be seen in the greater binding free energy contributions of the loop residues in the FtuFabI-54 binding complex when compared to the other two inhibitors (Figure 4) . Therefore, the broad spectrum activity of inhibitor 54 observed in F. tularensis, B. anthracis, and S. aureus likely results from the well-formed loop interaction and stabilization effects in these species. Antimicrobial activity was not observed in P. aeruginosa likely due to the presence of FabK and FabV. 24, 28 We postulate that broad spectrum inhibition of FabIs could be achieved by targeting residues affecting loop stabilization. This may point out a new strategy for rational design of novel inhibitors of FabI with bacteriostatic activity.
Derivatives of 54 and Implications for StructureBased Lead Optimization. To further delineate the structurally important functionalities of the chemotype of inhibitor 54, we selected a number of its analogues and tested their inhibitory activities against F. tularensis FabI (Supporting Information Table S1 ). Replacement of the indole group with a phenyl ring significantly decreased the activity (compounds C1 and C2), indicating that the 3-substituted indole is essential to binding and inhibition. On the other hand, substitution of the phenoxyl group with a phenyl ring, which was predicted to bind into the interior of the binding pocket, exhibited structure− activity relationships that were generally consistent with the binding interactions in the inner pocket. In particular, substituents at the ortho-position of the phenyl ring, such as an oxymethyl and chloride of C3 and C5, were more favorable than at the para-and meta-positions. Binding mode analysis indicated that the oxygen atom at the ortho-position formed a hydrogen-bonding interaction with Tyr-156, whereas the oxymethyl group at the para-and meta-positions more likely introduced a steric hindrance in the binding pocket. Interestingly, the indole ring with a bulky 2-substituted phenoxymethyl group (C10) showed potency comparable to inhibitor 54. The result is also consistent with our predicted binding mode for 54. We also tested several compounds bearing unique functionalities such as two indole groups (C14), which could potentially bind in both the interior and exterior pockets. However, compared to inhibitor 54, these bisite inhibitors did not exhibit higher potency or broad spectrum activity (Supporting Information Tables S1 and S2). Further structure-based lead optimization such as the refinement of the linker length and removal of hydrolyzable bonds within the linker could improve the activity of these types of inhibitors.
■ CONCLUSION
FabI is a well validated target, and a number of chemotypes have been identified for this target to date. The two 3-substituted indole inhibitors 54 and 57 identified in this study represent novel scaffolds with low micromolar potency and antibacterial activities. Both inhibitors had lower toxicity when compared to triclosan. Owing to the unique binding properties of inhibitor 54 and 57 associated with the indole group, it is possible that a combination of the two chemotypes may better achieve high potency and bacteriostatic activity. Moreover, our MD simulation-based virtual screening protocol proved to be an efficient approach in identifying novel and potent inhibitors of FabI with bacteriostatic activity by capturing a key element of inhibitor binding in a dynamic manner. Further lead optimization and refinement of the pharmacophore could improve the chances of developing broad spectrum inhibitors of FabI as therapeutics. 
